Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured .
LuminosticsFebruary 16, 2021 GMT
Luminostics’s Clip COVID Rapid Antigen Test uses a smartphone-based analyzer to obtain results in 30 minutes from nasal swabs in decentralized settings
Clip COVID’s emergency use authorization (EUA) in December 2020 closely followed the award of a $26.1 million contract to Luminostics by the National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA)
Luminostics is quickly ramping up production with a target capacity of 4,000,000+ tests per month by summer 2021
The company will soon seek EUA from the FDA for non-prescription, non-laboratory use of the Clip COVID Rapid Antigen Test
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the .
Meridian Bioscience Inc.February 3, 2021 GMT
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company’s SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio.
The funding will help Meridian expand production of Revogene® test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near the corporate headquarters in the Village of Newtown (Cincinnati, OH). The expansion will be completed in p
Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown
February 03, 2021 10:30 ET | Source: Meridian Bioscience Inc. Meridian Bioscience Inc. Cincinnati, Ohio, UNITED STATES
CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company s SARS-CoV-2 molecular diagnostic test on its Revogene
® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx
SM) initiative and an additional grant from JobsOhio.
The funding will help Meridian expand production of Revogene